News

Applied Clinical Trials Online19h

Response’s Investigational Small Molecule Inhibitor Shows Promising Post-GLP-1 Weight Management, Cardiometabolic Benefits

Results from a Phase II trial (NCT06640972) showed that patients treated with RDX-002 experienced significant reductions in ...
The Pharma Letter3h

Response offers positive Phase II data for post-GLP-1 obesity

US biotech Response Pharmaceuticals (Nasdaq: RSPN) has unveiled top-line Phase II results for its experimental obesity ...
GlobalData on MSN20h

Response’s post-GLP-1RA drug reduces weight rebound in Phase II

Response Pharmaceuticals’ drug has helped reduce the amount of weight a patient regains after treatment with glucagon-like ...